News Home

How Will the Market React to Editas Medicine Inc (EDIT) Stock Getting a Bearish Rating

Friday, March 31, 2023 03:55 PM | InvestorsObserver Analysts

Mentioned in this article

How Will the Market React to Editas Medicine Inc (EDIT) Stock Getting a Bearish Rating

Editas Medicine Inc (EDIT) stock has fallen 3.08% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bearish
Editas Medicine Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on EDIT!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With EDIT Stock Today?

Editas Medicine Inc (EDIT) stock is trading at $7.23 as of 3:55 PM on Friday, Mar 31, a gain of $0.20, or 2.84% from the previous closing price of $7.03. The stock has traded between $7.05 and $7.38 so far today. Volume today is below average. So far 990,383 shares have traded compared to average volume of 1,571,717 shares. To screen for more stocks like Editas Medicine Inc click here.

More About Editas Medicine Inc

Editas Medicine Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting disease-causing genes. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology. Click Here to get the full Stock Report for Editas Medicine Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App